A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

59 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-18

Study Completion Date

2020-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety profile and effectiveness of adalimumab in Korean intestinal Behcet's disease (BD) patients in routine clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease

NCT02505568

Behcet Disease

COMPLETED PHASE3

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

NCT00573794

Ulcerative Colitis

COMPLETED PHASE3

Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease

NCT04919252

Crohn's Disease and Ulcerative Colitis

UNKNOWN PHASE3

Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients

NCT04071405

Ulcerative Colitis

COMPLETED

A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants

NCT03535649

Colitis, Ulcerative

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intestinal Behcet's Disease (BD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects receiving adalimumab

The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must be an adult \>= 19 years
* Subjects who are eligible to be treated with adalimumab for intestinal Behcet's disease in accordance with the approved label in Korea
* Subjects provide written authorization form for use/disclose of personal health data prior to participating in this study

Exclusion Criteria

* Subjects who are contraindicated to any anti-TNF agent
* Female subjects who are pregnant or breast feeding
* Subjects who are participating in other interventional clinical trials

Minimum Eligible Age

19 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No